Provided by Tiger Fintech (Singapore) Pte. Ltd.

Xenon Pharmaceuticals

37.84
+0.22000.58%
Post-market: 37.840.00000.00%16:05 EDT
Volume:502.06K
Turnover:18.99M
Market Cap:2.89B
PE:-12.58
High:38.55
Open:37.65
Low:37.45
Close:37.62
Loading ...

Company Profile

Company Name:
Xenon Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
1996
Employees:
322
Office Location:
200-3650 Gilmore Way,Burnaby,British Columbia,Canada
Zip Code:
V5G 4W8
Fax:
604 484 3450
Introduction:
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.

Directors

Name
Position
Michael M. Tarnow
Chairman and Director
Simon N. Pimstone
Chief Executive Officer and Director
Dawn Svoronos
Director
Frank A. Holler
Director
Gary Patou
Director
Michael R. Hayden
Director
Mohammad Azab
Director
Richard Scheller
Director
Steven Gannon
Director

Shareholders

Name
Position
Simon N. Pimstone
Chief Executive Officer and Director
Ian C. Mortimer
President, Chief Financial Officer and Corporate Secretary
James R. Empfield
Senior Vice President, Drug Discovery of Xenon Pharmaceuticals USA Inc.
Y. Paul Goldberg
Senior Vice President, Clinical Development
Charles J. Cohen
Vice President, Biology
Ernesto Aycardi
Chief Medical Officer of Xenon Pharmaceuticals USA Inc.
Robin Sherrington
Executive Vice President, Business and Corporate Development